Fracture Risk in Patients on Hemodialysis: the Lower the Parathyroid Hormone the Better?
作者信息
Jadoul Michel Y, Labriola Laura
机构信息
Department of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
出版信息
Kidney Int Rep. 2024 Aug 29;9(10):2854-2856. doi: 10.1016/j.ekir.2024.08.023. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Fracture Risk in Patients on Hemodialysis: the Lower the Parathyroid Hormone the Better?血液透析患者的骨折风险：甲状旁腺激素越低越好？
Kidney Int Rep. 2024 Aug 29;9(10):2854-2856. doi: 10.1016/j.ekir.2024.08.023. eCollection 2024 Oct.
2
Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis.较低的甲状旁腺激素水平与日本血液透析患者骨折风险降低相关。
Kidney Int Rep. 2024 Jul 18;9(10):2956-2969. doi: 10.1016/j.ekir.2024.07.008. eCollection 2024 Oct.
3
Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis.血液透析患者的骨参数与髋部和股骨骨折风险
Clin J Am Soc Nephrol. 2016 Jun 6;11(6):1063-1072. doi: 10.2215/CJN.09280915. Epub 2016 Mar 29.
4
Diaphyseal femoral fracture due to severe vitamin D deficiency and low parathyroid hormone levels on long-term hemodialysis: a case report.长期血液透析致严重维生素 D 缺乏及甲状旁腺激素水平低下引起的股骨干骨折：病例报告。
Arch Osteoporos. 2020 Nov 12;15(1):179. doi: 10.1007/s11657-020-00849-7.
5
Relative hypoparathyroidism and hypoalbuminemia are associated with hip fracture in hemodialysis patients.相对甲状旁腺功能减退和低白蛋白血症与血液透析患者的髋部骨折有关。
Clin Nephrol. 2010 Feb;73(2):88-93. doi: 10.5414/cnp73088.
6
Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.重复血液透析对接受维生素D（骨化三醇）治疗的尿毒症患者循环免疫反应性甲状旁腺激素水平的急性影响。
Nephron. 1991;57(3):273-82. doi: 10.1159/000186275.
7
[Fragility Fractures in Hemodialysis Patients. Calcimimetics and fracture in hemodialysis patients.].[血液透析患者的脆性骨折。拟钙剂与血液透析患者的骨折。]
Clin Calcium. 2018;28(8):1107-1112.
8
Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.血清钙对血液透析患者甲状旁腺激素和碱性磷酸酶死亡率预测性的效应修饰作用：一项利用2005年至2012年台湾肾脏登记数据系统数据的调查
PLoS One. 2015 Jun 24;10(6):e0129737. doi: 10.1371/journal.pone.0129737. eCollection 2015.
9
Osteocytic perilacunar/canalicular turnover in hemodialysis patients with high and low serum PTH levels.高和低血清甲状旁腺激素水平血液透析患者的骨细胞性骨陷窝/骨小管更新。
Bone. 2018 Aug;113:68-76. doi: 10.1016/j.bone.2018.05.002. Epub 2018 May 5.
10
Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.根据残余肾功能水平分析血液透析患者矿物质骨代谢紊乱参数与死亡率的相关性
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1118-1127. doi: 10.2215/CJN.11931116. Epub 2017 May 9.
本文引用的文献
1
Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation.维持性血液透析期间使用依替卡肽与肾移植后甲状旁腺切除术的发生率
Kidney Int Rep. 2024 Apr 4;9(7):2146-2156. doi: 10.1016/j.ekir.2024.04.004. eCollection 2024 Jul.
2
Effects of PTH and PTH Hypersecretion on Bone: a Clinical Perspective.甲状旁腺激素及其分泌亢进对骨骼的影响：临床视角。
Curr Osteoporos Rep. 2020 Jun;18(3):103-114. doi: 10.1007/s11914-020-00574-7.
3
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.慢性肾脏病-矿物质和骨异常管理的临床实践指南
Ther Apher Dial. 2013 Jun;17(3):247-88. doi: 10.1111/1744-9987.12058.
4
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).改善全球肾脏病预后组织（KDIGO）慢性肾脏病-矿物质和骨异常（CKD-MBD）诊断、评估、预防及治疗临床实践指南。
Kidney Int Suppl. 2009 Aug(113):S1-130. doi: 10.1038/ki.2009.188.
5
The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations.测量白蛋白的检测方法对校正（“调整后”）钙浓度的影响。
Nephrol Dial Transplant. 2009 Jun;24(6):1834-8. doi: 10.1093/ndt/gfn747. Epub 2009 Jan 31.
6
Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).肾性骨营养不良的定义、评估及分类：改善全球肾脏病预后组织（KDIGO）的立场声明
Kidney Int. 2006 Jun;69(11):1945-53. doi: 10.1038/sj.ki.5000414.
7
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.慢性肾脏病骨代谢与疾病的K/DOQI临床实践指南
Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201.
8
Evolution of bone disease over 10 years in 135 patients with terminal renal failure.135例终末期肾衰竭患者10年骨病的演变
Br Med J. 1973 Nov 10;4(5888):315-9. doi: 10.1136/bmj.4.5888.315.
Zotero 插件